EP #516 - Patrick Pestalozzi & François Capel: How This Biomarker Can Detect Sepsis 3 Days Early
September 4, 2025
Co-produced by
Co-produced by
Timestamps:
6:00 - Tackling the early detection of sepsis
17:17 - Why obsess over hard challenges?
27:41 - Marketing a new biomarker
34:20 - Expanding and delegating to distributors
This episode was co-produced with Innovaud, the innovation and investment promotion agency for the canton of Vaud.
About Patrick Pestalozzi & François Capel:
Patrick Pestalozzi is a former management consultant and Silicon Valley executive with 3 decades of global experience, most recently as the Vice-President of Global Strategic Accounts for Mindmaze and as the CEO at GaitUp, a Mindmaze subsidiary. In 2024 he became the CEO at Abionic, a medtech EPFL spin-off founded back in 2010.
François Capel is an Innovation Director with 10+ years of experience driving innovation within fast-paced environments and innovation-driven industries. He is currently a full-time advisor at Innovaud, the innovation and investment promotion agency for the canton of Vaud.
During his chat with Merle and François, Patrick shared his experience as Abionic CEO. Abionic is on a mission to transform sepsis diagnoses through the use of nanofluids, and their flagship product, abioSCOPE®, a near-patient rapid diagnostic platform, delivers lab-quality results from a drop of blood within minutes, providing valuable clinical insights and actionable information at the point-of-care.
Don’t forget to give us a follow on Instagram, Linkedin, TikTok, and Youtube so you can always stay up to date with our latest initiatives. That way, there’s no excuse for missing out on live shows, weekly giveaways or founders' dinners.
.avif)
